Mural Oncology plc (MURA)
NASDAQ: MURA · Real-Time Price · USD
2.080
-0.010 (-0.48%)
At close: Oct 8, 2025, 4:00 PM EDT
2.090
+0.010 (0.48%)
After-hours: Oct 8, 2025, 5:34 PM EDT
Mural Oncology Employees
Mural Oncology had 116 employees as of December 31, 2024. The number of employees decreased by 1 or -0.85% compared to the previous year.
Employees
116
Change (1Y)
-1
Growth (1Y)
-0.85%
Revenue / Employee
n/a
Profits / Employee
-$1,268,552
Market Cap
36.12M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 116 | -1 | -0.85% |
| Dec 31, 2023 | 117 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MURA News
- 15 days ago - Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting - GlobeNewsWire
- 2 months ago - Mural Oncology Announces Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Mural Oncology Announces Number of Relevant Securities in Issue - GlobeNewsWire
- 5 months ago - FORM 8.1(a) & (b) - Mural Oncology plc - GlobeNewsWire
- 6 months ago - Mural Oncology Announces Plans to Explore Strategic Alternatives - GlobeNewsWire
- 7 months ago - Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges - Benzinga
- 7 months ago - Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 7 months ago - Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - GlobeNewsWire